Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: A randomized, open-label, crossover study

Acta Ophthalmologica

Volumn 93, Issue 4, 2015, Pages e254-e260

  Tanihara, Hidenobu ^a   Inoue, Toshihiro ^a   Yamamoto, Tetsuya ^b   Kuwayama, Yasuaki ^c,g   Abe, Haruki ^d,h   Suganami, Hideki ^e   Araie, Makoto ^f,i  

^a KUMAMOTO UNIVERSITY   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

^e KOWA COMPANY LTD   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g Fukushima Eye Clinic   (Japan)

^h NIIGATA UNIVERSITY OF HEALTH AND WELFARE   (Japan)

ⁱ The Mutualaid Association of Public School Teachers)   (Japan)

Author keywords

glaucoma; intra ocular pressure; K 115; Rho kinase inhibitor; ripasudil

Indexed keywords

PLACEBO; RIPASUDIL; ENZYME INHIBITOR; ISOQUINOLINE DERIVATIVE; K-115; RHO KINASE; SULFONAMIDE;

ABNORMAL SENSATION; ADULT; ARTICLE; ASTHENOPIA; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CORNEA DISEASE; CORNEA EROSION; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; IRITIS; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CIRCADIAN RHYTHM; CLINICAL TRIAL; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; INTRAOCULAR PRESSURE; MIDDLE AGED; MULTICENTER STUDY; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY;

ADULT; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; ENZYME INHIBITORS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; ISOQUINOLINES; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; RHO-ASSOCIATED KINASES; SULFONAMIDES; TONOMETRY, OCULAR;

EID: 84929395741     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12599     Document Type: Article

References (44)

1. AGIS Investigators (2000): The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429-440.
2. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, &, Lindenmuth K, (2000): Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 9: 134-142.
3. Bagga H, Liu JH, &, Weinreb RN, (2009): Intraocular pressure measurements throughout the 24 h. Curr Opin Ophthalmol 20: 79-83.
4. Coakes RL, &, Brubaker RF, (1978): The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol 96: 2045-2048.
5. Epstein DL, Rowlette LL, &, Roberts BC, (1999): Acto-myosin drug effects and aqueous outflow function. Invest Ophthalmol Vis Sci 40: 74-81.
6. Grosheva I, Vittitow JL, Goichberg P, et al., (2006): Caldesmon effects on the actin cytoskeleton and cell adhesion in cultured HTM cells. Exp Eye Res 82: 945-958.
7. Gulati V, Fan S, Zhao M, Maslonka MA, Gangahar C, &, Toris CB, (2012): Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Arch Ophthalmol 130: 677-684.
8. Heijl A, Leske MC, Bengtsson B, et al., (2002): Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120: 1268-1279.
9. Hirata A, Inatani M, Inomata Y, et al., (2008): Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia. Graefes Arch Clin Exp Ophthalmol 246: 51-59.
10. Honjo M, Tanihara H, Inatani M, et al., (2001a): Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 42: 137-144.
11. Honjo M, Inatani M, Kido N, et al., (2001b): Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol 119: 1171-1178.
12. Honjo M, Inatani M, Kido N, et al., (2002): A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. Exp Eye Res 75: 135-142.
13. Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, &, Araie M, (2007): Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci 48: 5549-5557.
14. Isobe T, Mizuno K, Kaneko Y, et al., (2014): Effects of K-115, a Rho-Kinase Inhibitor, on Aqueous Humor Dynamics in Rabbits. Curr Eye Res 39: 813-822.
15. Kameda T, Inoue T, Inatani M, et al., (2012): The effect of Rho-associated protein kinase inhibitor on monkey Schlemm's canal endothelial cells. Invest Ophthalmol Vis Sci 53: 3092-3103.
16. Kass MA, Heuer DK, Higginbotham EJ, et al., (2002): The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701-713.
17. Kass MA, Gordon MO, Gao F, et al., (2010): Delaying treatment of ocular hypertension. Arch Ophthalmol 128: 276-287.
18. Koga T, Koga T, Awai M, Tsutsui J, Yue BY, &, Tanihara H, (2006): Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp Eye Res 82: 362-370.
19. Konstas AG, Mantziris DA, &, Stewart WC, (1997a): Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 115: 182-185.
20. Konstas AG, Mantziris DA, Cate EA, &, Stewart WC, (1997b): Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 115: 975-979.
21. Kopczynski CC, &, Epstein DL, (2014): Emerging trabecular outflow drugs. J Ocul Pharmacol Ther 30: 85-87, in press.
22. Lippa EA, Carlson LE, Ehinger B, et al., (1992): Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 110: 495-499.
23. Liu JH, Zhang X, Kripke DF, &, Weinreb RN, (2003a): Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 44: 1586-1590.
24. Liu JH, Bouligny RP, Kripke DF, &, Weinreb RN, (2003b): Nocturnal elevation of intraocular pressure is detectable in the sitting position. Invest Ophthalmol Vis Sci 44: 4439-4442.
25. Liu JH, Kripke DF, &, Weinreb RN, (2004): Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 138: 389-395.
26. Liu JH, Medeiros FA, Slight JR, &, Weinreb RN, (2009): Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 116: 449-454.
27. McCannel CA, Heinrich SR, &, Brubaker RF, (1992): Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans. Graefes Arch Clin Exp Ophthalmol 230: 518-520.
28. Narumiya S, (1996): The small GTPase Rho: cellular functions and signal transduction. J Biochem 120: 215-228.
29. Okka M, Tian B, &, Kaufman PL, (2004): Effect of low-dose latrunculin B on anterior segment physiologic features in the monkey eye. Arch Ophthalmol 122: 1482-1488.
30. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, &, Autelitano A, (2000): Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 41: 2566-2573.
31. Rao PV, Deng PF, Kumar J, &, Epstein DL, (2001): Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 42: 1029-1037.
32. Rao PV, Deng P, Sasaki Y, &, Epstein DL, (2005): Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res 80: 197-206.
33. Reiss GR, Lee DA, Topper JE, &, Brubaker RF, (1984): Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci 25: 776-778.
34. Sagawa H, Terasaki H, Nakamura M, et al., (2007): A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. Exp Neurol 205: 230-240.
35. Stewart WC, Konstas AG, Nelson LA, &, Kruft B, (2008): Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 115: 1117-1122.
36. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, &, Araie M, (2008): Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 126: 309-315.
37. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, &, Araie M, (2013a): Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol 131: 1288-1295.
38. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, &, Araie M, (2013b): Phase 2 randomized clinical study of a Rho Kinase Inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 156: 731-736.
39. Tian B, Kaufman PL, Volberg T, Gabelt BT, &, Geiger B, (1998): H-7 disrupts the actin cytoskeleton and increases outflow facility. Arch Ophthalmol 116: 633-643.
40. Tian B, Gabelt BT, Geiger B, &, Kaufman PL, (2009): The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res 88: 713-717.
41. Tokushige H, Inatani M, Nemoto S, et al., (2007): Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 48: 3216-3222.
42. Tokushige H, Waki M, Takayama Y, &, Tanihara H, (2011): Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats. Curr Eye Res 36: 964-970.
43. Uehata M, Ishizaki T, Satoh H, et al., (1997): Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994.
44. Williams RD, Novack GD, van Haarlem T, Kopczynski C, & AR-12286 Phase 2A Study Group (2011): Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol 152: 834-841.